Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Dutch who wrote (954)	6/20/1999 7:09:00 PM
From: SG	Read Replies (1) \| Respond to of 965

Thanks, will check it out. CNTO would have been a pretty good pick at 30 when i knew how desperate Crohn's people were for a treatment but I didn't have the $$. SG

To: Dutch who wrote (954)	6/23/1999 8:15:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 965

Thread and Dutch: --Got any opinion on Isis-2302 vs. Remicade. I am just starting to look into Isis, but I see CNTO is already there for Crohn's disease. I guess I should have known that, seems like you hear Remicade come up a lot on the BBRS call each week, plus I guess CNTO is getting a lot of good PR with the chance for a takeover or merger frequently mentioned. I'll make my question more specific--how does the use of steriods fit in with each, does a patient still stay on steriods with Remicade, cant say I know anything about it yet. Anyway, thanks for any pointers thread. OT Dutch--you have got to be kidding, RMBS is way overpriced--I don't play with put options anymore, and I don't short, but no way would I be buying Rambus. Here are a couple reasons from me: Message 9943341 and see thestreet.com as well: thestreet.com